Amrouche Tahar, Lammi Sarah, Drider Djamel
Laboratoire Qualité Et Sécurité Des Aliments, Faculté Des Sciences Biologiques Et Des Sciences Agronomiques, Université Mouloud Mammeri, 15 000, Tizi Ouzou, Algeria.
UMR Transfrontalière BioEcoAgro INRAE 1158, Université de Lille (ULille), 59000, Lille, France.
Probiotics Antimicrob Proteins. 2025 Jun;17(3):1356-1367. doi: 10.1007/s12602-024-10404-2. Epub 2024 Nov 30.
Probiotics and prebiotics have been suggested as natural agents against viral infections and dysbiosis and may encourage clinical applications. This review aims to analyze the main and recent advances related to viral infections such as Covid-19 and its gastrointestinal complications, antiviral immunity generated and possible preventive role that probiotics and/or prebiotics can play in controlling and promoting antiviral immunity. The literature search was performed through a critical analysis of relevant publications reported in PubMed and Scopus databases on clinical trials and assays conducted in vitro on colon cells and in vivo on mice. Some studies using probiotics and prebiotics for the prevention of viral infection in different age groups are discussed. Covid-19 patients have been shown to suffer from gastrointestinal complications in addition to respiratory symptoms due to interactions between the respiratory system and the gastrointestinal tract infected with SARS-CoV-2. Unfortunately, therapies used to prevent (or treat) symptoms of Covid-19 have proven to be of limited effectiveness. In addition, the lack of access to coronavirus vaccines around the world and vaccine hesitancy continue to hamper control of Covid-19. It is therefore crucial to find alternative methods that can prevent disease symptoms. Evidence-based efficacy of certain probiotics (Lactobacillus and Bifidobacterium) that may be useful in viral infections was shown with immunomodulatory properties (pro-inflammatory mediators reduction), promoting antiviral immunity (antibodies production, virus titers) and controlling inflammation (anti-inflammatory effect), as well as viral clearance and antimicrobial potential against opportunistic bacteria (anti-dysbiosis effect). But, available data about clinical application of probiotics in Covid-19 context remain limited and relevant scientific investigation is still in its early stages. Also, evidence for prebiotics potential in this field is limited, since the exact mechanism involved in systemic immune modulation by these compounds is till now unknown. Thus, further research is necessary to explore in the viral infection context the mechanism by which gut and lung interact in the presence of probiotics and prebiotics through more animal and clinical experiments.
益生菌和益生元已被认为是对抗病毒感染和生态失调的天然制剂,并可能推动其临床应用。本综述旨在分析与病毒感染(如新冠病毒及其胃肠道并发症)、所产生的抗病毒免疫以及益生菌和/或益生元在控制和促进抗病毒免疫中可能发挥的预防作用相关的主要及最新进展。通过对PubMed和Scopus数据库中报道的关于在结肠细胞上进行的体外试验以及在小鼠身上进行的体内试验的相关出版物进行批判性分析来开展文献检索。讨论了一些使用益生菌和益生元预防不同年龄组病毒感染的研究。已表明新冠患者除了有呼吸道症状外,还会因感染新冠病毒的呼吸系统与胃肠道之间的相互作用而出现胃肠道并发症。不幸的是,用于预防(或治疗)新冠症状的疗法已被证明效果有限。此外,全球范围内无法获取冠状病毒疫苗以及疫苗犹豫情绪继续阻碍对新冠的控制。因此,找到能够预防疾病症状的替代方法至关重要。某些益生菌(乳酸杆菌和双歧杆菌)在病毒感染中可能有用,其具有免疫调节特性(减少促炎介质)、促进抗病毒免疫(产生抗体、病毒滴度)和控制炎症(抗炎作用)以及病毒清除和针对机会性细菌的抗菌潜力(抗生态失调作用),这些都显示了基于证据的有效性。但是,关于益生菌在新冠背景下临床应用的现有数据仍然有限,相关科学研究仍处于早期阶段。而且,益生元在该领域潜力的证据也有限,因为这些化合物参与全身免疫调节的确切机制至今尚不清楚。因此,有必要通过更多的动物和临床实验,在病毒感染背景下探索在益生菌和益生元存在的情况下肠道与肺部相互作用的机制。